ABVC BioPharma is a clinical stage biopharmaceutical company. Co.'s wholly owned subsidiaries, American BriVision Corporation, focuses on the development of ABV-1701 Vitreous Substitute for Vitrectomy. Through its another wholly owned subsidiary, BioLite Holding Inc., Co. conducts clinical research and trials of various drug candidates, including: ABV-1504 for the treatment of Major Depressive Disorder, ABV-1505 to treat Attention-Deficit Hyperactivity Disease, ABV-1501 for the treatment of Triple Negative Breast Cancer, ABV-1703 for the treatment of Pancreatic Cancer, ABV-1702 to treat Myelodysplastic syndromes and ABV-1601 Depression in Cancer Patients. We show 3 historical shares outstanding datapoints in our ABVC shares outstanding history coverage, used to compute ABVC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ABVC market cap history over the course of time is important for investors
interested in comparing ABVC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ABVC versus a peer is one thing; comparing
ABVC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ABVC can fluctuate over the course of history.
With this page we aim to empower investors researching ABVC by allowing them to research the ABVC market cap history. |
Free ABVC Email Alerts:
Video: The Importance of Market Cap
